Market Research Logo

Europe Diabetes Drugs Market Forecast 2019-2027

Europe Diabetes Drugs Market Forecast 2019-2027
KEY FINDINGS

The CAGR for the European market of diabetes drugs is expected to be 5.09% for the forecast period of 2019-2027. The increase in life expectancy contributes to the increase in the number of diseases prevailing in the region, especially diabetes. Implications caused by diabetes such as CVDs, kidney failure, foot ulcers and damage to the eyes have made people in Europe more conscious about diabetes management.

MARKET INSIGHTS

The growing number of individuals with diabetes contributes to the market growth in this region. Due to the same reason, there are increased number of admissions in hospital, both in emergency and non-emergency. These cases are generally associated with factors like sedentary lifestyle and poor diet. Key growth drivers include a preference for foreign drugs rather than domestically manufactured products. Several global pharmaceutical companies have already announced plans to build factories in the European region.

COMPETITIVE INSIGHTS

Leading market players in the European market for diabetes drugs are Novo Nordisk A/S, Xoma Corp., B.Braun Melsungen Ag, Astellas Pharma, Macrogenics, Inc., Glaxosmithkline, Pfizer, Xeris Pharmaceuticals, AstraZeneca Plc., Eli Lilly And Company, Sanofi, Diavacs Inc., Albireo Pharma Inc. and Merck.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Rising Prevalence Of Type 2 Diabetes
3.2.2. Insulin Market Is Anticipated To Generate Highest Revenue
4. Market Determinants
4.1. Market Drivers
4.1.1. Increase In Prevalence Of Diabetes
4.1.2. Advances In Insulin Technology
4.1.3. Growing Elderly Population
4.2. Market Restraints
4.2.1. Stringent Regulatory Conditions And Guidelines For Biosimilar Drugs
4.2.2. Lack Of Awareness Among People
4.2.3. Cost Sensitivity Issues
4.3. Market Opportunities
4.3.1. Development Of New Formulations
4.3.2. Increasing Research And Development
4.4. Market Challenges
4.4.1. Fierce Market Competition
4.4.2. Rising Concerns In Scientific Community
4.4.3. Gaps In National-level Diabetes Management Plans
4.4.4. Poor Storage Conditions And Distribution Policies For Insulin
5. Market Segmentation
5.1. Market By Diabetes Type 2019-2027
5.1.1. Type 1
5.1.2. Type 2
5.2. Market By Product Class 2019-2027
5.2.1. Insulin
5.2.1.1. Fast Acting Insulin
5.2.1.2. Intermediate Acting Insulin
5.2.1.3. Long-acting Insulin
5.2.2. Non-insulin
5.2.2.1. Dpp-4 Inhibitor
5.2.2.2. Glp-1 Receptors Agonists
5.2.2.3. Sglt-2 Inhibitors
5.2.2.4. Other Non-insulin Drugs
6. Key Analytics
6.1. Porter’s Five Force Analysis
6.1.1. Threat Of New Entrants
6.1.2. Threat Of Substitute
6.1.3. Bargaining Power Of Suppliers
6.1.4. Bargaining Power Of Buyers
6.1.5. Threat Of Competitive Rivalry
6.2. Opportunity Matrix
6.3. Etymology Of Diabetes Drugs Market
6.4. Legal, Policy And Regulatory Issues
7. Geographical Analysis
7.1. Europe
7.1.1. The United Kingdom
7.1.2. France
7.1.3. Germany
7.1.4. Russia
7.1.5. Italy
7.1.6. Denmark
7.1.7. Norway
7.1.8. Austria
7.1.9. Switzerland
7.1.10. Sweden
7.1.11. Netherlands
7.1.12. Rest Of Europe
8. Company Profiles
8.1. Eli Lilly And Company
8.1.1. Overview
8.1.2. Products Portfolio
8.1.3. Swot Analysis
8.1.4. Strategic Initiatives
8.2. Astrazeneca Plc.
8.2.1. Overview
8.2.2. Product Portfolio
8.2.3. Swot Analysis
8.2.4. Strategic Initiatives
8.3. B.Braun Melsungen Ag
8.3.1. Overview
8.3.2. Product Portfolio
8.3.3. Scot Analysis
8.3.4. Strategic Analysis
8.4. Novo Nordisk A/S
8.4.1. Overview
8.4.2. Products Portfolio
8.4.3. Swot Analysis
8.4.4. Strategic Initiatives
8.5. Sanofi
8.5.1. Overview
8.5.2. Products Portfolio
8.5.3. Swot Analysis
8.5.4. Strategic Initiatives
8.6. Diavacs Inc.
8.6.1. Overview
8.6.2. Product Portfolio
8.6.3. Swot Analysis
8.7. Xoma Corp.
8.7.1. Overview
8.7.2. Product Portfolio
8.7.3. Swot Analysis
8.7.4. Strategic Initiatives
8.8. Albireo Pharma Inc.
8.8.1. Overview
8.8.2. Product Portfolio
8.8.3. Swot Analysis
8.9. Macrogenics, Inc.
8.9.1. Overview
8.9.2. Product Portfolio
8.9.3. Swot Analysis
8.10. Astellas Pharma
8.10.1. Overview
8.10.2. Product Portfolio
8.10.3. Swot Analysis
8.10.4. Strategic Initiatives
8.11. Glaxosmithkline
8.11.1. Overview
8.11.2. Product Portfolio
8.11.3. Swot Analysis
8.12. Merck
8.12.1. Overview
8.12.2. Product Portfolio
8.12.3. Swot Analysis
8.12.4. Strategic Initiatives
8.13. Pfizer
8.13.1. Overview
8.13.2. Product Portfolio
8.13.3. Swot Analysis
8.13.4. Strategic Initiatives
8.14. Xeris Pharmaceuticals
8.14.1. Overview
8.14.2. Product Portfolio
8.14.3. Swot Analysis
8.14.4. Strategic Initiatives
Table List
Table 1 Europe Diabetes Drugs Market 2019-2027 ($ Million)
Table 2 Europe Diabetes Drugs Market By Diabetes Types 2019-2027, ($ Million)
Table 3 Europe Diabetes Drugs Market In Type 1 Diabetes 2019-2027 ($ Million)
Table 4 Europe Diabetes Drugs Market In Type 2 Diabetes 2019-2027 ($ Millions)
Table 5 Europe Diabetes Drugs Market By Product Class 2019-2027 ($ Millions)
Table 6 Europe Diabetes Drugs Market In Insulin Type 2019-2027 ($ Million)
Table 7 Europe Diabetes Drugs Market In Insulin By Types 2019-2027 ($ Million)
Table 8 Europe Insulin Market In Fast Acting Insulin 2019-2027 ($ Million)
Table 9 Europe Insulin Market In Intermediate Acting Insulin 2019-2027 ($ Million)
Table 10 Europe Insulin Market In Long Acting Insulin 2019-2027 ($ Million)
Table 11 Europe Diabetes Drugs Market In Non-insulin Drugs 2019-2027 ($ Million)
Table 12 Europe Diabetes Drugs Market In Non-insulin Drugs By Types 2019-2027 ($ Million)
Table 13 Europe Non-insulin Drugs Market In Dpp-4 Inhibitor 2019-2027 ($ Million)
Table 14 Europe Non-insulin Drugs Market In Glp-1 Receptors Agonists 2019-2027 ($ Million)
Table 15 Europe Non-insulin Drugs Market In Sglt-2 Inhibitors 2019-2027 ($ Million)
Table 16 Europe Non-insulin Drugs Market In Other Non-insulin Drugs 2019-2027 ($ Million)
Table 17 Europe Diabetes Drugs Market By Country 2019-2027 ($ Million)
Figures List
Figure 1 Europe Diabetes Drugs Market 2019-2027 ($ Billion)
Figure 2 Europe Diabetes Drugs Market, By Type 2 Diabetes 2019-2027 ($ Million)
Figure 3 Average Life Expectancy At Birth In 2017, By Gender (In Years)
Figure 4 Porter’s Five Forces Analysis Of Diabetes Drugs Market
Figure 5 The United Kingdom Diabetes Drugs Market 2019-2027 ($ Million)
Figure 6 France Diabetes Drugs Market 2019-2027 ($ Million)
Figure 7 Germany Diabetes Drugs Market 2019-2027 ($ Million)
Figure 8 Russia Diabetes Drugs Market 2019-2027 ($ Million)
Figure 9 Italy Diabetes Drugs Market 2019-2027 ($ Million)
Figure 10 Denmark Diabetes Drugs Market 2019-2027 ($ Million)
Figure 11 Norway Diabetes Drugs Market 2019-2027 ($ Million)
Figure 12 Austria Diabetes Drugs Market 2019-2027 ($ Million)
Figure 13 Switzerland Diabetes Drugs Market 2019-2027 ($ Million)
Figure 14 Sweden Diabetes Drugs Market 2019-2027 ($ Million)
Figure 15 Netherlands Diabetes Drugs Market 2019-2027 ($ Million)
Figure 16 Rest Of Europe Diabetes Drugs Market 2019-2027 ($ Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report